Convatec Group PLC (LON:CTEC)
London · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 4.42B -11.5% |
| Revenue (ttm) | 1.88B +5.7% |
| Net Income | 93.46M -43.0% |
| EPS | 0.05 -41.5% |
| Shares Out | 1.95B |
| PE Ratio | 48.39 |
| Forward PE | 14.40 |
| Dividend | 0.05 (2.31%) |
| Ex-Dividend Date | Aug 20, 2026 |
| Volume | 5,890,175 |
| Open | 225.00 |
| Previous Close | 225.60 |
| Day's Range | 223.20 - 227.60 |
| 52-Week Range | 193.00 - 259.30 |
| Beta | 0.76 |
| Analysts | Strong Buy |
| Price Target | 298.01 (+31.86%) |
| Earnings Date | Aug 4, 2026 |
About Convatec Group
Convatec Group PLC engages in the development, manufacturing, and sale of medical products, services and technologies for the management of chronic conditions in Europe, North America, and internationally. The company offers advanced wound care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns. It also provides ostomy care solutions, including devices, accessories, and services for people with a stoma resulting from colorect... [Read more]
Financial Performance
In 2025, Convatec Group's revenue was $2.44 billion, an increase of 6.55% compared to the previous year's $2.29 billion. Earnings were $175.00 million, a decrease of -8.38%.
Financial numbers in USD Financial StatementsAnalyst Summary
According to 18 analysts, the average rating for CTEC stock is "Strong Buy." The 12-month stock price target is 298p, which is an increase of 31.86% from the latest price.
News
Dover To Buy Leistung Engineering To Boost Business In India
(RTTNews) - Dover Corporation (DOV), a maker of industrial products, said that it has inked a deal to acquire Leistung Engineering Pvt. Ltd., an Indian cryogenic valves maker, for an undisclosed sum. ...
ConvaTec Group H1 Earnings Call Highlights
ConvaTec Group LON: CTEC said it remained on track to meet its 2026 financial targets after reporting 5% organic revenue growth in the first half, excluding the impact of its InnovaMatrix skin-substit...
Convatec Group Earnings Call Transcript: H1 2026
H1 2026 saw solid revenue and EPS growth, with strong performance across all segments and new products scaling up. Guidance for FY 2026 is reaffirmed, with accelerated growth and margin expansion expected in H2, supported by robust order visibility and ongoing productivity initiatives.
Convatec Group Quarterly report: H1 2026
Convatec Group has published its H1 2026 quarterly earnings report on August 4, 2026.
Convatec Group Slides: H1 2026
Convatec Group has posted slides in relation to its H1 2026 quarterly earnings report, which was published on August 4, 2026.
UK's Convatec expects higher second-half margin, launches $200 million buyback
British medical products maker Convatec on Tuesday forecast its second-half operating margin to be materially higher than the first half, and pointed to accelerating demand for its infusion care pro...
Medical product maker Convatec warns of higher cost from Iran War
British medical products maker Convatec on Thursday posted slower organic revenue growth for the first four months of 2026 and its CEO warned of higher costs in 2027 due to the Iran conflict, sendin...
Convatec Group Transcript: Trading update
Broad-based growth across all categories supports unchanged 2026 guidance, with new product launches and capacity expansions expected to accelerate growth from 2027. Margin and EPS targets remain on track, despite inflation and regulatory uncertainties.
Convatec Group Earnings release: Trading update
Convatec Group released its earnings on May 21, 2026, summarizing the period's financial results.
Convatec Group Slides: Trading update
Convatec Group has posted slides in relation to its latest quarterly earnings report, which was published on May 21, 2026.
Convatec's Advanced Wound Care Innovation Leads the Industry at European Wound Management Association (EWMA) 2026
LONDON--(BUSINESS WIRE)--Convatec, a leading medical products and technology company focused on chronic condition management, takes to the stage to showcase the breadth, depth and momentum behind its ...
Convatec Group Transcript: CMD 2026
The Accelerate strategy builds on a successful turnaround, targeting 6%-8% organic revenue growth, mid-20s operating margin, and double-digit EPS growth. Growth is driven by robust innovation, new product launches across all categories, capacity expansion, and disciplined capital allocation.
Convatec Group Slides: FY 2026
Convatec Group has posted slides in relation to its FY 2026 quarterly earnings report, which was published on April 9, 2026.
Convatec Introduces Co-Branded eakin freeseal® Ostomy Seal in North America, Expanding the ESENTA™ Family of Accessories
BOSTON & LONDON--(BUSINESS WIRE)--Convatec, a leading medical products and technologies company focused on solutions for the management of chronic conditions, and Eakin Healthcare, a specialist provid...